Picture Campus Berlin-Buch at BIO2023 BerlinBioCube Start-up Center 650x100px
Document › Details

Optibrium Ltd.. (2/17/20). "Press Release: Optibrium Appoints Dr Tim Hohm as Director of Commercial Strategy and Business Development". Cambridge.

Organisations Organisation Optibrium Ltd.
  Group Optibrium (Group)
  Organisation 2 Novo Nordisk A/S
Products Product StarDrop™ software
  Product 2 bioinformatics (biological software and databases)
Persons Person Hohm, Tim (Optibrium 202002– Director of Commercial Strategy and Business Development before Novo Nordisk)
  Person 2 Segall, Matthew (Matt) (Optibrium 2009– CEO + co-founder before Inpharmatica/BioFocus)

Tim Hohm to further develop Optibrium’s sales and business strategy for global market expansion

Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Tim Hohm as Director of Commercial Strategy and Business Development. Tim will be responsible for leading the Company’s commercial strategy and sales processes, with a focus on further expanding Optibrium’s global customer base. In addition to managing existing customer relationships and new business opportunities, Tim’s role will involve market and customer insight in relation to the Company’s StarDrop™ and Augmented Chemistry™ products and services, helping to guide the continued development of Optibrium’s in silico drug discovery technologies and artificial intelligence services.

Tim joins Optibrium from Novo Nordisk where he held a position as Senior Competitive Intelligence Manager. His role at Novo Nordisk covered digital health and delivery technology with responsibilities including strategy development, defining target product profiles and building business cases for pipeline projects and external opportunities. Tim has a PhD in Computational Biology from ETH Zurich and research experience with optimisation heuristics and quantitative modelling of gene regulatory networks. Tim’s natural sciences background is complemented with an MBA from the internationally recognised Copenhagen Business School.

Dr Matthew Segall, CEO at Optibrium, said: “Tim’s background in business strategy, and combined experience in the drug development value chain, pharmaceutical research and development and computational sciences, will be invaluable in attaining our ambitious expansion plans and sustained commercial growth. We are delighted to welcome Tim to our senior team and look forward to him developing Optibrium’s global customer base, supporting our objectives to extend and enhance our innovative drug discovery software and services.”

Dr Tim Hohm, Director of Commercial Strategy and Business Development at Optibrium, said: “I am pleased to be joining Optibrium at this exciting time, following the launch of the Company’s StarDrop™ 6.6 software and recent introduction of the new Augmented Chemistry™ platform. I look forward to working with the team to support these products, engage with Optibrium’s existing customers and develop new opportunities to further expand the global user base.”

For further information on Optibrium, please visit, contact or call +44 1223 815900.


Notes to Editors:

[Photo] Tim Hohm as Director of Commercial Strategy and Business Development
[Photo] Tim Hohm (left) and Matthew Segall (right)
For high resolution images please email
To opt-out from receiving press releases from Zyme Communications please email To view our privacy policy, please click here.

Media contact

Sarah Jeffery
Zyme Communications
Phone: +44 (0) 7771 730919

John Norman
Head of Marketing
Phone: +44 (0)1223 815903

About Optibrium Ltd

Optibrium provides elegant software solutions for small molecule design, optimisation and data analysis. Optibrium’s lead product, StarDrop™, is a comprehensive suite of integrated software with a highly visual and user-friendly interface. StarDrop™ enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the discovery process. The company’s new Augmented Chemistry™ products and services deliver ground-breaking artificial intelligence technologies that continuously learn from all available data to supplement researchers experience and skills.

Founded in 2009, Optibrium is headquartered in Cambridge, UK with offices in Boston and San Francisco, USA. Optibrium continues to develop new products and research novel technologies to improve the efficiency and productivity of the drug discovery process. Optibrium works closely with its broad range of customers and collaborators that include leading global pharma, agrochemical and flavouring companies, biotech and academic groups.

For further information visit or join in discussions on improving the productivity of drug discovery at

F5-6 Blenheim House, Cambridge Innovation Park
Denny End Road, Cambridge
CB25 9PB, UK

Tel: +44 1223 815900
Fax: +44 1223 815907

Optibrium Limited, registered in England and Wales No. 06715106. Optibrium™, StarDrop™ and Augmented Chemistry™ are trademarks of Optibrium Ltd.

Record changed: 2022-02-04


Picture Campus Berlin-Buch at BIO2023 Location of Future Innovation 650x200px

More documents for Optibrium (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group ASCO 2023 Annual Meeting Connecting Cancer 650x300px

» top